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Abstract
Background: The Finnish Diabetes Prevention Study (DPS) was a randomized controlled trial, which showed that it is
possible to prevent type 2 diabetes by lifestyle changes. The aim of the present study was to examine whether the lifestyle
intervention had an effect on the ten-year mortality and cardiovascular morbidity in the DPS participants originally
randomized either into an intervention or control group. Furthermore, we compared these results with a population-based
cohort comprising individuals of varying glucose tolerance states.
Methods and Findings: Middle-aged, overweight people with IGT (n=522) were randomized into intensive intervention
(including physical activity, weight reduction and dietary counseling), or control ‘‘mini-intervention’’ group. Median length
of the intervention period was 4 years and the mean follow-up was 10.6 years. The population-based reference study cohort
included 1881 individuals (1570 with normal glucose tolerance, 183 with IGT, 59 with screen-detected type 2 diabetes, 69
with previously known type 2 diabetes) with the mean follow-up of 13.8 years. Mortality and cardiovascular morbidity data
were collected from the national Hospital Discharge Register and Causes of Death Register. Among the DPS participants
who consented for register linkage (n=505), total mortality (2.2 vs. 3.8 per 1000 person years, hazard ratio HR=0.57, 95% CI
0.21–1.58) and cardiovascular morbidity (22.9 vs. 22.0 per 1000 person years, HR=1.04, 95% CI 0.72–1.51) did not differ
significantly between the intervention and control groups. Compared with the population-based cohort with impaired
glucose tolerance, adjusted HRs were 0.21 (95% CI 0.09–0.52) and 0.39 (95% CI 0.20–0.79) for total mortality, and 0.89 (95%
CI 0.62–1.27) and 0.87 (0.60–1.27) for cardiovascular morbidity in the intervention and control groups of the DPS,
respectively. The risk of death in DPS combined cohort was markedly lower than in FINRISK IGT cohort (adjusted HR 0.30,
95% CI 0.17–0.54), but there was no significant difference in the risk of CVD (adjusted HR 0.88, 95% CI 0.64–1.21).
Conclusions: Lifestyle intervention among persons with IGT did not decrease cardiovascular morbidity during the first 10
years of follow-up. However, the statistical power may not be sufficient to detect small differences between the intervention
and control groups. Low total mortality among participants of the DPS compared with individuals with IGT in the general
population could be ascribed to a lower cardiovascular risk profile at baseline and regular follow-up.
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Type 2 diabetes mellitus (T2DM) as well as lesser degrees of
impaired glucose regulation are known to increase the risk of
cardiovascular diseases (CVD), in particular coronary heart disease,
peripheral vascular diseases, and stroke [1,2,3]. Several lifestyle
interventionstudieshaveshownthat itispossibletoprevent ordelay
the development of manifest T2DM in individuals with impaired
glucose tolerance (IGT) [4,5,6,7,8,9,10]. Furthermore, there is
evidence that some drugs used for the treatment of hyperglycemia
are able to delay the development of T2DM among high risk
groups, i.e. in persons with IGT [11,12,13].
However, the ultimate goal of prevention of T2DM is to
improve the prognosis and overall quality of life of affected
individuals, and with regard to health policy, also to prevent
increasing costs of the treatment of T2DM and its complications.
There are no randomized lifestyle intervention trials in persons
with IGT to show that lifestyle changes would reduce CVD
mortality or morbidity. Recently, the 20-year results from the
China Da Qing Diabetes Prevention Study [10] showed sustained
protection against diabetes but did not give a definite answer to the
question whether lifestyle changes are beneficial in terms of CVD
morbidity or mortality. Also in the DPS, which was the first
individually randomized controlled lifestyle intervention trial, the
risk of T2DM was substantially lowered even after discontinuation
of active intervention and some improvement was seen in the main
CVD risk factors [5,14,15]. Furthermore, the greater the lifestyle
changes were the lower was the risk of T2DM [5,9].
The main aim of the present study was to examine whether the
lifestyle intervention applied in the DPS had an effect on mortality
and CVD morbidity by comparing the mortality and CVD
morbidity data of the intensive lifestyle intervention group to
control group. In addition, we also present follow-up data for a
population-based ‘‘native control group’’ (the FINRISK 1992
cohort) [16], because due to the study design also the control
group of the DPS can be considered as a ‘‘mini-intervention
group’’.
Methods
The DPS study
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. The DPS is a clinical trial with five participating
centers (Helsinki, Kuopio, Turku, Tampere, and Oulu) in Finland.
Details on the DPS study design, methods, and procedures have
been published previously [5,14,17]. Briefly, study participants
were recruited mainly by screening of high-risk groups who
voluntarily responded to local advertisements. The inclusion
criteria were 1) age 40 to 64 years at screening, 2) body mass
index (BMI) .25 kg/m
2 at screening, and 3) the mean value of
two 75-g oral glucose tolerance tests (OGTT) in the IGT range
based on WHO 1985 criteria [18]. Exclusion criteria included
recent (within 6 months) CVD event. The randomization of
participants started in 1993 and continued until 1998. At the
enrollment visit the study physician wrote the names of eligible
participants on the centrally-produced randomization list in
consecutive order. The study nurse who was responsible for
scheduling the visits did not have access to the list. Randomization
was stratified by centre, sex, and the mean 2-hour plasma glucose
value (7.8–9.4 mmol/l or 9.5–11.0 mmol/l). The DPS was
designed to be large enough to be able to detect a 35% reduction
in diabetes incidence with 80% power (beta=20%) at the 2-tailed
5% significance level (alpha=5%) [17].
A total of 522 overweight men and women were randomly
allocated to one of the two treatment modalities, the intensive diet-
exercise counseling group (n=265, the proportion of women 66%)
or the control group (n=257, the proportion of women 69%). The
laboratory personnel were not aware of the group allocation but
naturally the participants and staff members involved with the
intervention were, so the study was only partly masked. The
participants randomized to intensive lifestyle intervention were
given individualized counseling by the study nutritionists to
achieve the lifestyle goals. They were also advised to increase
their level of physical activity, and voluntary physical activity
sessions were offered. The lifestyle goals were 1) weight reduction
of $5%, 2) ,30% of the daily energy intake from fat, 3) ,10% of
the daily energy intake from saturated fat, 4) fiber intake $15
grams per 1000 kcal, and 5) moderately intense physical activity
$30 minutes per day. The control participants were given general
health behavior information at randomization [14]. The median
length of the active intervention period was 4 years (range 1–6
year).
All participants had an annual OGTT, a medical history, and a
physical examination with measurements of height (without shoes),
weight (in light indoor clothes), waist circumference (midway
between the lowest rib and iliac crest) and systolic and diastolic
blood pressure. Serum total cholesterol, HDL-cholesterol and
triglycerides were determined from fasting samples using an
enzymatic assay method.
FINRISK 1992 survey
The FINRISK 1992 survey was carried out as a part of the
FINMONICA cardiovascular risk factor survey, which is de-
scribed in detail elsewhere [16]. In brief, a stratified random
sample of 8000 people living in three geographical areas in
Finland (eastern, south-western and southern Finland), was drawn
from the National Population Register. The participants received
a postal questionnaire on medical history, socioeconomic back-
ground, and health behavior, and an invitation to a clinical
examination. Three thousand three hundred people of the original
study sample were aged between 45 and 64 years. Of these, 2642
(80%) people who had participated in the original clinical
examination were invited to this study. Of them, 2087 (79%)
attended the OGTT. Totally, glucose tolerance status and all
necessary variables for the analyses were available for 1881
participants.
The OGTT procedure and glucose tolerance classification was
based on the WHO 1985 recommendations [18]. Plasma glucose
concentration was determined in a central laboratory using a
glucose dehydrogenase method (Hoffmann-La Roche, Basel,
Switzerland).
Individuals who reported that they have diabetes did not have
an OGTT and were classified as known T2DM. Individuals with
fasting plasma glucose level $7.8 mmol/l or 2 h plasma glucose
$11.1 mmol/l were classified as having screen-detected type 2
diabetes (ST2DM). Those with 2 h plasma glucose $7.8 and
,11.1 mmol/l, and fasting plasma glucose ,7.8 mmol/l were
classified as having IGT.
Total mortality and cardiovascular morbidity
Data on health status were collected through computerized
register linkage to two nationwide health registers: the Hospital
Discharge Register and the Causes of Death Register, using the
national personal identification number.
Data on all patients discharged dead or alive from all hospitals
in Finland have been recorded in a computerized Hospital
Discharge Register since year 1968. The diagnoses for hospital-
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Classification of Diseases (ICD) version 8 during 1967 to 1986,
version 9 during 1987 to 1995, and version 10 since 1996.
Both registers were complete with information until the end of
year 2006. End points during follow-up were total mortality, and
incident cardiovascular events (fatal and non-fatal), defined as the
ICD 8 and 9 codes 401–449, and ICD 10 codes I10–I79. These
codes include acute coronary events, coronary heart disease, stroke
and hypertensive disease. In both registers the diagnoses are
assigned by the physician treating the patient. Diagnostic
classification in these registers has been validated against diagnoses
derived by myocardial infarction registers, and the concordance
was found high [19,20].
In order to estimate the baseline CVD risk according to the
measured risk factors at baseline, we calculated for each study
person their 10-year probability to have an CVD-event according
to the Framingham risk equation [21].
Ethical considerations
The study protocols of both the DPS study and FINRISK
survey were approved by the ethics committee of the National
Public Health Institute in Helsinki, Finland. All study participants
provided informed consent prior to the clinical assessments. In the
DPS study, 17 participants did not give their consent for the
register linkages, and they were thus excluded from this study.
Statistical methods
Participants were followed up until December 31, 2006, with a
median follow-up time of 10.6 years for the DPS trial and 13.8
years for the FINRISK Study cohorts. We calculated mortality
and CVD incidence rates separately for the DPS and FINRISK
study cohorts, and by glucose tolerance status at the initial
examination. In univariate analyses, log-rank test was used to
assess differences between the glucose tolerance groups. In
multivariate Cox models, the relationship between glucose
tolerance at baseline and CVD during the follow-up was further
analyzed, taking into account possible confounding factors
including age, sex, smoking, history of CVD, systolic blood
pressure and total cholesterol. All the analyses were done for the
entire study cohorts and after exclusion persons who had had a
CVD event before the first examination. Analyses were done with
the statistics package Stata version 9.2 [22].
Results
Baseline data
The DPS intervention and control groups were similar with
regard to the main baseline variables (Table 1). Compared with
the FINRISK cohort, proportion of smokers (7% vs. 20%–24%)
and proportion of men (32% vs. 41%–55%) was lower.
Furthermore, mean levels of systolic blood pressure (p,0.01 for
all) and serum total cholesterol (p,0.001, except for the FINRISK
diabetic group with p=0.172) were lower among the DPS study
participants compared with the FINRISK groups with distur-
bances in glucose metabolism.
Compared with the normoglycemic people in the FINRISK
study, all the other groups (i.e. hyperglycemic people) had elevated
triglyceride levels, and lower levels of HDL cholesterol (p,0.001
for all comparisons).
Among the DPS participants, 8.2% in the intervention group
and 8.1% in the control group had CVD in the outset of the study.
In the FINRISK study cohorts there was an increasing trend in the
prevalence of CVD from 9.0% in the normoglycemic group to
34.8% in patients with known T2DM. Thus, the baseline
prevalence of CVD in the DPS cohort was at the same level as
in the FINRISK normoglycemic group.
The estimated 10-year Framingham CVD risk in both of the
DPS cohorts was similar to that in the FINRISK normoglycemic
group.
Table 1. Baseline characteristics of the participants in the DPS and FINRISK1992 studies by glucose tolerance.
Study: DPS DPS FINRISK FINRISK FINRISK FINRISK
Glucose tolerance: IGT (intervention) IGT (control) Normal IGT ST2DM T2DM
Number of subjects: n 257 248 1570 183 59 69
Age, years 55.467.3 55.066.9 53.766.0 55.865.8 55.965.4 55.666.3
Sex, % men 34.2 31.5 40.9 50.6 55.2 50.7
BMI, kg/m
2 31.464.6 31.264.5 26.863.9 29.865.2 31.766.1 30.564.9
Smoking, % 7.0 7.3 20.3 24.0 23.7 14.5
Fasting glucose, mmol/l 6.160.8 6.260.7 5.460.6 6.060.6 7.862.2 10.463.0
2-h glucose, mmol/l 8.961.5 8.961.5 5.561.1 8.860.9 14.063.8 -
Total cholesterol, mmol/l 5.661.0 5.660.9 5.961.0 6.061.1 6.261.2 5.861.3
HDL cholesterol, mmol/l 1.2160.31 1.2260.28 1.4260.35 1.2560.31 1.1960.29 1.1460.31
Triglycerides, mmol/l 1.6960.80 1.7660.76 1.4960.86 2.1761.52 2.7461.82 2.7861.92
Systolic blood pressure, mmHg 139.6617.7 136.2617.4 140.3619.4 148.8619.5 150.2621.1 145.6620.8
Diastolic blood pressure, mmHg 85.769.4 85.6610.0 84.9611.0 88.8611.0 88.3612.9 85.169.8
Drug treatment for lipid abnormalities, % 4.3 6.1 2.3 2.8 1.7 10.1
Drug treatment for elevated blood pressure, % 27.7 31.5 13.5 31.9 37.9 36.8
Baseline CVD*, % 8.2 8.1 9.0 19.7 25.4 34.8
Framingham 10-year CVD-probability, %: 14.3 13.2 14.4 19.4 31.0 29.3
*Values are means6standard deviation unless otherwise noted. Baseline CVD: At least one cardiovascular event (ICD 8 and 9 codes: 401–449; ICD 10 codes : I10–I79)
according to the Finnish Hospital discharge register before participation in the DPS or FINRISK studies.
doi:10.1371/journal.pone.0005656.t001
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The total number of deaths during the follow-up were 214
(11%) in the FINRISK cohort, and 16 (3%) in the DPS cohort
(Table 2). Age- and sex-adjusted Kaplan-Meier estimates of the
total mortality are presented in Figure 1. The mortality rates were
lowest in the DPS intervention and control groups, being 2.2 and
3.8 per 1000 person-years, respectively (HR=0.57, 95% CI 0.21–
1.58, intervention group of DPS compared to the control group).
In the FINRISK cohort, the mortality rates were 6.6, 16.4, 21.0,
and 28.8 per 1000 person-years in the normoglycemic, IGT,
ST2DM and known T2DM groups, respectively. Compared with
the FINRISK IGT group, adjusted HR were 0.21 (95% CI 0.09–
0.52) and 0.39 (95% CI 0.20–0.79) for total mortality in the
intervention and control groups of the DPS, respectively. The risk
of death in the combined DPS cohort (both intervention and
control arms) was markedly lower when compared with the
FINRISK IGT cohort (adjusted HR 0.30, 95% CI 0.17–0.54)
CVD morbidity
In the DPS cohort, after a median follow-up time of 10.2 years,
there were 57/257 new CVD events in the intervention group and
54/248 in the control group (Table 2). These correspond to the
incidence rates of 22.9 and 22.0 per 1000 person-years
(HR=1.04, 95% CI: 0.72–1.51 DPS intervention group com-
pared to the control group). Men and women had a similar CVD
incidence whether groups were analyzed separately or combined
(data not shown). In addition, no statistically significant differences
were found between the intervention and control groups of the
DPS with regard to coronary artery angioplasty or by-pass surgery
nor drug treatment for dyslipidemia and blood pressure (data not
shown).
Figure 2 shows the age- and sex-adjusted Kaplan-Meier
estimates of cumulative incidence of fatal and non-fatal CVD
events. The incidence rates show that the FINRISK known
diabetic group had the highest rate of CVD. Both DPS study
groups had markedly lower incidence rates compared to the
FINRISK IGT group (Table 2). However, there were no
statistically significant differences in CVD between the two IGT
groups of the DPS study and the FINRISK IGT group after
adjustment for baseline risk factors. Hazard ratios for CVD
morbidity in the DPS intervention and control groups were 0.89
(95% CI: 0.62–1.27) and 0.87 (95%CI: 0.60–1.27), respectively,
compared with the FINRISK IGT group.
We also examined CVD risk after excluding people with a
history of CVD at baseline. The analyses showed essentially
similar results as presented above for all participants, i.e. the
highest CVD risk was found in people with T2DM. Further, in
sensitivity analyses, we replicated all the analyses above by
excluding early CVD-events, i.e. events occurring during the first
3 years after the baseline health examinations. The results
remained essentially unchanged compared with the results
presented here (data not shown).
CVD incidence in relation to main risk factors
In the entire FINRISK cohort, excluding persons with history of
CVD, baseline risk factors were strongly associated with CVD
incidence (Table 3). When adjusting for age, sex and smoking, all
the examined risk factors, with the exception for total cholesterol
Table 2. Total mortality and cardiovascular events during the follow-up of the DPS and FINRISK studies by glucose tolerance.
Study: DPS DPS FINRISK FINRISK FINRISK FINRISK
Glucose tolerance: IGT (intervention) IGT (control) Normal IGT ST2DM T2DM
Number of persons 257 248 1570 183 59 69
Total mortality:
Person-years, years 2752 2653 20966 2315 713 797
Median follow-up, years 10.6 10.6 13.9 13.8 13.8 13.8
Number of deaths, n 6 10 138 38 15 23
Rate per 1000 person years 2.2 3.8 6.6 16.4 21.0 28.8
95% confidence interval (1.0–4.9) (2.0–7.0) (5.6–7.8) (11.9–22.6) (12.7–34.9) (19.2–43.4)
Hazard ratio (95% CI), unadjusted 0.15 (0.06–0.35) 0.26 (0.13–0.52) 0.40(0.28–0.57) 1.00 1.29(0.71–0.2.37) 1.77(1.05–2.98)
p: ,0.001 ,0.001 ,0.001 (ref) 0.407 0.032
Hazard ratio (95% CI), adjusted* 0.21 (0.09–0.52) 0.39 (0.20–0.79) 0.52 (0.36–0.74) 1.00 1.08 (0.56–2.06) 1.96 (1.15–3.34)
p: 0.001 0.009 ,0.001 (ref) 0.824 0.014
Cardiovascular events:
Person-years, years 2488 2452 18878 1855 533 581
Median follow-up, years 10.2 10.2 13.8 13.8 9.5 8.4
CVD events, n 57 54 364 74 33 39
Rate per 1000 person years 22.9 22.0 19.3 39.9 62.0 67.2
95% confidence interval (17.7–29.7) (16.9–28.7) (17.4–21.4) (31.8–50.1) (44.0–87.1) (49.1–91.9)
Hazard ratio (95% CI), unadjusted 0.59 (0.41–0.83) 0.56 (0.40–0.80) 0.48 (0.37–0.62) 1.00 1.58 (1.04–2.39) 1.69 (1.11–2.39)
p: 0.003 0.001 ,0.001 (ref) 0.033 0.014
Hazard ratio (95% CI), adjusted* 0.89 (0.62–1.27) 0.87 (0.60–1.27) 0.67 (0.51–0.88) 1.00 1.39 (0.90–2.15) 1.64 (1.02–2.15)
p: 0.528 0.481 0.004 (ref) 0.133 0.042
*adjusted for age, sex, smoke, baseline CVD, systolic blood pressure and total cholesterol.
doi:10.1371/journal.pone.0005656.t002
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of CVD. Among the DPS participants, the relationship was less
clear. Nevertheless, the effects of triglycerides, HDL cholesterol,
blood pressure and fasting and 2-h post load plasma glucose levels
on CVD risk were quite similar in these two cohorts.
When all the variables in Table 3 were simultaneously
considered in a stepwise multivariate selection procedure, age,
sex, smoking and HDL cholesterol remained statistically signifi-
cant predictors of CVD in the DPS cohort. Additionally including
the DPS treatment group into the model did not improve
prediction. In the FINRISK cohort, besides age, sex and smoking,
also systolic blood pressure, waist circumference and medication
for high blood pressure were statistically significant predictors of
CVD.
Finally, we analyzed the effects of changes in selected risk factors
within the first year of the DPS study on the CVD risk (Table 4).
In unadjusted analyses, changes in body weight and diastolic blood
pressure were statistically significant predictors, but after further
adjustment for age, sex and smoking, only change in diastolic
blood pressure remained as statistically significant predictor of
CVD in a way that reduction of diastolic blood pressure
diminished the risk of CVD.
Figure 2. Cumulative incidence of total CVD in the DPS and FINRISK studies. Adjusted for age and sex.
doi:10.1371/journal.pone.0005656.g002
Figure 1. Mortality in the DPS and FINRISK studies. Adjusted for age and sex.
doi:10.1371/journal.pone.0005656.g001
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Our main aim was to examine whether a lifestyle intervention
with weight reduction, dietary counseling and increasing physical
activity could reduce total mortality and CVD morbidity in the
Finnish DPS. The CVD morbidity was identical for the DPS
intervention and control groups. Thus, we found no evidence of
overall CVD risk modification by the DPS lifestyle intervention in
persons with IGT. In keeping with findings from numerous
previous prospective studies [1,2,3], both IGT and T2DM in the
FINRISK cohort increased the risk of CVD.
Interestingly, total mortality in both groups of the DPS
participantswasmarkedlylowerwhencomparedwiththeFINRISK
participants with IGT. The mortality data, however, should be
interpreted with caution due to a small number of cases and as the
difference could reflect the distinct selection procedures of the study
populations,leadingtodivergentriskprofilesasshownbydifferences
in the risk factor levels and the calculated Framingham 10-year
CVD-probability. However, besides these factors, also the regular
follow-up and health consciousness of the DPS study participants
could explain the low mortality among them.
Table 3. CVD risk in relation to baseline variables in the DPS and FINRISK studies.
DPS study FINRISK study
Univariate HR
(95% CI) p
Adj. HR
(95% CI) p
Univariate HR
(95% CI) p
Adj. HR
(95% CI) p
Age 1.34 (1.09–1.63) 0.004 1.57 (1.40–1.75) ,0.001
Sex (1 men, 0 women) 2.64 (1.72–4.07) ,0.001 1.90 (1.55–2.34) ,0.001
Smoking (1 yes, 0 no) 2.55 (1.36–4.81) 0.004 1.48 (1.17–1.87) 0.001
BMI 0.82 (0.64–1.05) 0.110 0.93 (0.72–1.20) 0.576 1.42 (1.30–1.55) ,0.001 1.40 (1.27–1.55) ,0.001
Waist 1.15 (0.89–1.49) 0.288 1.06 (0.80–1.41) 0.683 1.59 (1.44–1.76) ,0.001 1.48 (1.31–1.68) ,0.001
Total cholesterol 0.93 (0.72–1.20) 0.560 0.92 (0.70–1.20) 0.535 1.17 (1.06–1.29) 0.002 1.11 (1.00–1.23) 0.051
Triglycerides 1.46 (1.12–1.89) 0.005 1.44 (1.11–1.86) 0.006 1.31 (1.19–1.43) ,0.001 1.22 (1.09–1.36) 0.001
HDL cholesterol 0.60 (0.44–0.83) 0.002 0.65 (0.47–0.89) 0.007 0.75 (0.67–0.84) ,0.001 0.84 (0.75–1.95) 0.005
Systolic blood pressure 1.27 (1.04–1.55) 0.020 1.19 (0.94–1.52) 0.145 1.46 (1.34–1.59) ,0.001 1.31 (1.19–1.45) ,0.001
Diastolic blood pressure 1.13 (0.90–1.43) 0.287 1.07 (0.84–1.36) 0.598 1.35 (1.23–1.49) ,0.001 1.28 (1.16–1.42) ,0.001
Fasting glucose 1.30 (0.96–1.77) 0.089 1.24 (0.91–1.68) 0.176 1.35 (1.24–1.47) ,0.001 1.28 (1.17–1.40) ,0.001
2-h glucose 1.28 (0.88–1.86) 0.198 1.35 (0.95–1.91) 0.099 1.32 (1.18–1.48) ,0.001 1.25 (1.11–1.41) ,0.001
Lipid medication (1 yes, 0 no) 1.13 (0.37–3.51) 0.829 1.08 (0.38–3.12) 0.884 1.97 (1.94–4.11) 0.070 1.72 (0.82–3.62) 0.153
Blood pressure medication (1 yes, 0 no) 1.82 (1.16–2.84) 0.009 1.80 (1.12–2.89) 0.015 2.33 (1.83–2.97) ,0.001 2.11 (1.65–2.71) ,0.001
Univariate HR: Each of the variables listed, respectively, is included in a model alone.
Adj. HR: Each of the variables listed, respectively, is included in a model together with age, sex and smoking.
Excluding individuals who had CVD before participation to the study. For continuous variables, the hazard ratio is given per 1 standard deviation unit.
doi:10.1371/journal.pone.0005656.t003
Table 4. Changes in CVD risk factors and their relation to CVD events during follow-up in the DPS.
Change from baseline to year 1 Hazard ratio per 1 standard deviation change
DPS intervention DPS control Intervention and control groups combined
mean6standard
deviation
mean6standard
deviation Univariate HR (95% CI) p Adj. HR (95% CI) p
Weight 24.565.0 21.063.7 1.27 (1.02–1.59) 0.032 1.22 (0.94–1.58) 0.144
Waist 24.365.2 21.464.9 1.12 (0.90–1.41) 0.317 1.10 (0.87–1.40) 0.417
Total cholesterol 20.1260.73 20.1060.72 0.84 (0.66–1.08) 0.181 0.87 (0.68–1.11) 0.258
Triglycerides 20.1960.56 20.0260.67 1.00 (0.80–1.26) 0.975 1.06 (0.85–1.33) 0.583
HDL cholesterol 0.0560.19 0.0260.17 1.05 (0.84–1.30) 0.672 1.05 (1.05–1.32) 0.696
Systolic BP 25.2614.3 21.5614.7 1.16 (0.93–1.44) 0.203 1.22 (0.98–1.52) 0.072
Diastolic BP 24.768.6 22.869.5 1.25 (1.02–1.53) 0.028 1.31 (1.07–1.59) 0.007
Glucose, 0 h 20.2360.68 0.0460.66 1.23 (0.93–1.64) 0.146 1.22 (0.90–1.66) 0.192
Glucose, 2 h 20.8061.86 20.2862.18 1.24 (0.95–1.63) 0.120 1.20 (0.92–1.58) 0.177
Univariate HR: Each of the variables listed, respectively, is included in a model alone.
Adj. HR: Each of the variables listed, respectively, is in included in a model together with age, sex and smoking.
Excluding individuals who had CVD before participation into the study.
doi:10.1371/journal.pone.0005656.t004
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overall follow-up of 7 years were 4.3 and 7.4 cases per 100 person-
years in the intervention and control groups, respectively (hazard
ratio 0.57, 95% CI 0.44 to 0.79, p,0.001) [9]. Whereas there is
firm evidence that lifestyle changes prevent T2DM in well
controlled long-term trials [4,5,6,7,8,9,10], little is known whether
a lifestyle intervention could modify CVD mortality or morbidity
in such trial settings. Recently, 20-years follow-up results from the
Chinese Da Qing Diabetes Prevention Study showed no
statistically significant differences in CVD morbidity or mortality
between the intervention and control groups, although a non-
significant 17% reduction was seen in CVD mortality in the
combined (diet and/or physical activity) intervention group [10].
Yet, the incidence of T2DM was 43% lower in the intervention
group compared with the control group after 20-years of follow-
up. In the non-randomized Malmo ¨ Preventive Trial with a 12-
year follow-up of men with IGT, both the over-all and ischemic
heart disease mortality were lower among those who were
participating in the diet and exercise intervention group,
compared with routine treatment group [23], but due to the
non-randomized study design these results should be considered
with precaution.
The DPS was not initially planned to examine the effect of
lifestyle intervention on total mortality or CVD morbidity.
Therefore, the statistical power may not be sufficient to detect
small differences in CVD events between the intervention and
control groups in the DPS. Another explanation for the equal
CVD risk in the lifestyle intervention and control groups in the
DPS may be that lifestyle changes were not extensive enough to
result in significant CVD risk reduction even though they were
sufficient to reduce the rate of progression to T2DM. Nevertheless,
in addition to the improvement in glycemia, some beneficial
changes were achieved in other risk factors of CVD in the DPS
[5,9,15]. Importantly, both the intervention and control group
participants in the DPS were regularly examined by the study
physician. There was no difference in drug treatment for elevated
serum lipids or blood pressure, and also the number of invasive
treatments for coronary artery disease was similar in both groups.
The DPS participants irrespective of the randomization group
were well motivated and carefully monitored in terms of their
health status, and they also had more favorable risk profile
compared with the FINRISK ‘true control cohort’. Thus, we
suggest that they represented the healthier proportion of persons
with IGT, and this may explain why no significant effects on CVD
morbidity could be observed by lifestyle intervention. This view is
strongly supported by their low mortality rates irrespective of the
randomization group when compared to FINRISK control
persons. However, the present results do not exclude the possibility
that a study design targeted a priori at CVD prevention in people
at high risk for T2DM by lifestyle modification as applied in the
DPS could have an effect on CVD morbidity. Furthermore, a
longer follow-up period may be needed to obtain a definite answer
to this question.
As in many previous studies, low HDL-cholesterol and high
triglycerides showed to be the main risk factors for CVD in both
persons with IGT and T2DM [1,2,24]. Weight reduction and
increase in physical activity are the most important lifestyle factors
to improve these lipid abnormalities. Recent results of the
treatment of very obese people by bariatric surgery show that
weight reduction indeed may improve the prognosis of obese
people, and not only T2DM risk but also total mortality was
reduced [25]. Suggestive evidence to this direction was also
observed in the present study; BMI was a risk factor for CVD only
in the FINRISK cohort, with no active intervention in this regard.
Furthermore, in univariate analyses on the DPS study persons 1-
year weight loss seemed to reduce cardiovascular risk among IGT
persons free of CVD at baseline, with 5 kg weight reduction
resulting in 27% CVD risk reduction; however, the effect was no
longer significant in analysis adjusted for age, sex, and smoking.
Also the early results from the US Diabetes Prevention Program
showed improvement in CVD risk factors after intensive lifestyle
intervention compared with the placebo or metformin treatment,
but no difference in CVD events between the groups was observed
after 3 years follow-up [26].
In conclusion, the DPS lifestyle intervention that resulted in
marked decrease in the incidence of T2DM even after the active
intervention period did not decrease the risk of CVD during a 10-
year follow-up. A lower initial CVD risk profile and regular follow-
up may explain the observed lower mortality among the DPS
participants when compared to the population based IGT or
normoglycemic cohorts. In the future, lifestyle intervention studies
to prevent T2DM should be focused on individuals, who besides
an increased risk of T2DM also have a markedly increased CVD
risk. The future studies should also be sufficiently powered to
detect modest differences in CVD morbidity or mortality. Finally,
meta-analyses of multiple intervention trials may offer an
opportunity to solve the question on the effects of lifestyle changes
on CVD morbidity and mortality among persons with IGT.
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